[Outcomes of the long-term treatment with a novel mucolytic drug pulmozin in mucoviscidosis patients].
OBJECTIVE
To study clinical effectiveness and safety of a new mucolytic drug pulmozim (Switzerland) adjuvant to basic therapy in mucoviscidosis patients of different age in Russia.


METHODS
15 patients with mucoviscidosis aged 5-36 years, functional lung capacity and FEV-1 at least 40% received pulmozim for 30 days. The drug was given in a single daily dose 2.5 mg in inhalations. The study included three stages: initial 14 days--discontinuation of all mucolytic drugs, 30-day course of pulmozim, 14-day follow-up without pulmozim and other mucolytics.


RESULTS
Pulmozim in the above regimen was effective in patients with mixed and moderate mucoviscidosis. The drug facilitates respiration, improves sputum rheology, normalizes general condition of the patient, is simple for use, has good organoleptic properties.


CONCLUSIONS
Pulmozim is an effective mucolytic drug in combined treatment of mucoviscidosis.
N I
NI
Kapranov
T E
TE
Gembitskaia
O I
OI
Simonova
E L
EL
Amelina
L F
LF
Kovaleva
L A
LA
Shabalova
N Iu
NIu
Kashirskaia
M E
ME
Faustova
D000293:Adolescent; D000328:Adult; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003850:Deoxyribonuclease I / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D011994:Recombinant Proteins; D003850:Deoxyribonuclease I